Walleye Capital’s TherapeuticsMD TXMD Stock Holding History

Walleye Capital’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-467	Closed	-$31	–	1513
2021 Q1	$31	Buy	+467	New	+$36.6K	﹤0.01%	1101

Other funds holding TXMD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

CWG

C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Walleye Capital's TXMD Position: Q2 2021 in Review

Walleye Capital sold out of TherapeuticsMD (TXMD) in Q2 2021, closing a stake of 467 shares — an estimated $31 sold.

Walleye Capital first reported a position in TXMD in Q1 2021 and held it in 1 quarter. The position peaked at $31 in Q1 2021. 154 funds tracked by Wall St. Rank hold TXMD as of Q2 2021.

Walleye Capital reported no remaining TherapeuticsMD position as of Q2 2021 after selling out during the quarter.
Walleye Capital sold 467 TherapeuticsMD shares in Q2 2021, an estimated $31.
Walleye Capital first reported a position in TherapeuticsMD in Q1 2021 and held it in 1 quarter.
Walleye Capital's TherapeuticsMD position peaked at $31 in Q1 2021.
154 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2021.

Based on Walleye Capital's 13F filing for Q2 2021, filed 16 Aug 2021.